Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Ähnlich wie HealthFLD AI Platform for Fatty Liver Detection Gains FDA Approval
Ähnlich wie HealthFLD AI Platform for Fatty Liver Detection Gains FDA Approval (20)
Kürzlich hochgeladen
Kürzlich hochgeladen (20)
HealthFLD AI Platform for Fatty Liver Detection Gains FDA Approval
- 1. HealthFLD AI Platform for Fatty Liver Detection Gains FDA Approval
- 2. Nanox provides artificial intelligence-informed (AI) medical imaging services that enable the identification of those living with undetected chronicdiseases. In February 2024, Nanox received FDA approval for the use of its fully automatedHealthFLD AI software in analyzing liver attenuationfromCT scans among the general population.
- 3. This is important, as some 24 percent of US adults have MASLD (formerlynon-alcoholicfatty liver disease), which is a metabolic disease connectedwith obesity. Having MASLD increases the risk of severe liver issues such as cirrhosis, as well as cardiovascular disease. It’s asymptomaticuntil it progressesto the advanced liver fibrosis stage, with invasive and expensive liver biopsy as the standard diagnostic.
- 4. The HealthFLD solution supportsearly diagnosis of fatty liver through a qualitative and quantitativeanalysis of routine abdomen and chest CT scans amongpatients in the 18 to 75 age range. Reliable, automated,non-invasive, and scalable to large patient populations, this AI assessment approach is poised to significantly improve health outcomes.